Proteomic Patterns of Nipple Aspirate Fluids Obtained by SELDI-TOF: Potential for New Biomarkers to Aid in the Diagnosis of Breast Cancer

Nipple aspirate fluid (NAF) has been used for many years as a potential non-invasive method to identify markers for breast cancer risk or early detection. Because individual markers have not been optimal, we are exploring the use of surface enhanced laser desorption and ionization time of flight (SELDI-TOF) mass spectrometry to identify patterns of proteins that might define a proteomic signature for breast cancer. SELDI-TOF was used to analyze a study set of NAF samples that included 12 women with breast cancer and 15 healthy controls (the latter included three women with an abnormal mammogram but subsequent normal biopsy). In this preliminary report, we present data showing that SELDI analysis of NAF is rapid, reproducible, and capable of identifying protein signatures that appear to differentiate NAF samples from breast cancer patients and healthy controls, including those with an abnormal mammogram who were later proven to be biopsy normal.

[1]  B. Fisher.  The evolution of paradigms for the management of breast cancer: a personal perspective. , 1992, Cancer research.

[2]  R. Miike,et al.  Breast cancer risk associated with abnormal cytology in nipple aspirates of breast fluid and prior history of breast biopsy. , 1993, American journal of epidemiology.

[3]  M. Nguyen,et al.  Breast-cancer diagnosis with nipple fluid bFGF , 2000, The Lancet.

[4]  Ralph Scully,et al.  Dynamic Changes of BRCA1 Subnuclear Location and Phosphorylation State Are Initiated by DNA Damage , 1997, Cell.

[5]  D. Fairclough,et al.  Carcinoembryonic antigen in breast nipple aspirate fluid. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[6]  M. Stoeckli,et al.  Direct profiling of proteins in biological tissue sections by MALDI mass spectrometry. , 1999, Analytical chemistry.

[7]  B. Hulka.  ASPO Distinguished Achievement Award Lecture , 1991 .

[8]  P. Engstrom,et al.  Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk. , 1997, British Journal of Cancer.

[9]  M. Ringnér,et al.  Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks , 2001, Nature Medicine.

[10]  A. Lapolla,et al.  Evaluation of IgG glycation levels by matrix-assisted laser desorption/ionization mass spectrometry. , 1997, Rapid communications in mass spectrometry : RCM.

[11]  E. Petricoin,et al.  Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip , 2000 .

[12]  K. Chew,et al.  Nipple aspirate cytology for the study of breast cancer precursors. , 1983, Journal of the National Cancer Institute.

[13]  N. Petrakis.  ASPO Distinguished Achievement Award Lecture. Studies on the epidemiology and natural history of benign breast disease and breast cancer using nipple aspirate fluid. , 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[14]  B. Trock,et al.  Blood-borne indicators of breast cancer and their use in experimental, medical oncologic, and prevention studies , 1996 .

[15]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[16]  M. Swift.  Ionizing radiation, breast cancer, and ataxia-telangiectasia. , 1994, Journal of the National Cancer Institute.

[17]  Barbara L. Smith,et al.  Nipple fluid carcinoembryonic antigen and prostate-specific antigen in cancer-bearing and tumor-free breasts. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E. Diamandis,et al.  Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[19]  A. Shimizu,et al.  Analysis of serum protein precipitated with antiserum by matrix-assisted laser desorption ionization/time-of-flight and electrospray ionization mass spectrometry as a clinical laboratory test , 1995, Journal of the American Society for Mass Spectrometry.

[20]  G. Eichele,et al.  Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2 , 1997, Nature.

[21]  W. Donegan.  Evaluation of a palpable breast mass. , 1993, The New England journal of medicine.

[22]  M. Lise,et al.  Protein profiles in sera of patients with malignant cutaneous melanoma. , 2000, Rapid communications in mass spectrometry : RCM.

[23]  J. Elmore,et al.  Ten-year risk of false positive screening mammograms and clinical breast examinations. , 1998, The New England journal of medicine.

[24]  H. R. Bergen,et al.  Rapid determination of transferrin isoforms by immunoaffinity liquid chromatography and electrospray mass spectrometry. , 2001, Clinical chemistry.

[25]  R. Platzman,et al.  What is ionizing radiation? , 1959, Scientific American.